iwAL 2019 Session V
Novel Approaches and Targeted Therapies in AML
Session V of iwAL 2019 saw targeted therapies and novel approaches in AML discussed,
with e-learning webinars from Marina Konopleva, MD, Mark Levis, MD, PhD, Naval Daver, MD, Richard Stone, MD, and Torsten Haferlach, MD.
Various therapies came into focus, including MDM2 inhibitors, venetoclax-based therapy, FTL3+ targets, antibody-drug conjugates, liposomal formations, HDAC inhibitors and syk inhibition.
Presentations
Liposomal Advances (CPX-351)
Richard Stone, MD
Dana-Farber Cancer Institute, Boston, MA
Dana-Farber Cancer Institute, Boston, MA
5 May, 2019
MDM2 inhibition in R/R AML
Marina Konopleva, MD, PhD
University of Texas MD Anderson Cancer Center, Houston, TX
University of Texas MD Anderson Cancer Center, Houston, TX
5 May, 2019
New Therapies for FLT3+ AML
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
5 May, 2019
Venetoclax-based therapy in first-line treatment of AML
Marina Konopleva, MD, PhD
University of Texas MD Anderson Cancer Center, Houston, TX
University of Texas MD Anderson Cancer Center, Houston, TX
5 May, 2019
Antibody-drug conjugates
Naval Daver, MD
University of Texas MD Anderson Cancer Center, Houston, TX
University of Texas MD Anderson Cancer Center, Houston, TX
5 May, 2019
HDAC Inhibitors
Richard Stone, MD
Dana-Farber Cancer Institute, Boston, MA
Dana-Farber Cancer Institute, Boston, MA
5 May, 2019
Personalized treatment strategies in AML
Torsten Haferlach, MD
Munich Leukemia Laboratory, Munich, Germany
Munich Leukemia Laboratory, Munich, Germany
5 May, 2019
syk-inhibition
Richard Stone, MD
Dana-Farber Cancer Institute, Boston, MA
Dana-Farber Cancer Institute, Boston, MA
5 May, 2019
